688321 微芯生物
已收盘 03-23 15:00:00
资讯
新帖
简况
每周股票复盘：微芯生物（688321）西格列他钠复方制剂获临床试验批准
证券之星 · 03-22 01:55
每周股票复盘：微芯生物（688321）西格列他钠复方制剂获临床试验批准
微芯生物(688321.SH)：西格列他钠二甲双胍缓释片获得药物临床试验批准
智通财经 · 03-16
微芯生物(688321.SH)：西格列他钠二甲双胍缓释片获得药物临床试验批准
微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书
智通财经 · 03-13
微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书
礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参
每日经济新闻 · 03-12
礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参
微芯生物（688321）披露以集中竞价交易方式首次回购公司股份公告，3月11日股价下跌1.02%
证券之星 · 03-11
微芯生物（688321）披露以集中竞价交易方式首次回购公司股份公告，3月11日股价下跌1.02%
微芯生物(688321.SH)拟8000万元至1.2亿元回购股份
智通财经 · 03-10
微芯生物(688321.SH)拟8000万元至1.2亿元回购股份
3月3日微芯生物跌6.88%，中航优选领航混合发起A基金重仓该股
证券之星 · 03-03
3月3日微芯生物跌6.88%，中航优选领航混合发起A基金重仓该股
微芯生物（688321）披露向特定对象发行A股股票发行情况报告书，2月25日股价上涨1.56%
证券之星 · 02-25
微芯生物（688321）披露向特定对象发行A股股票发行情况报告书，2月25日股价上涨1.56%
微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议
智通财经 · 02-03
微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议
微芯生物（688321）披露持股5%以上股东部分被冻结股份已解冻的公告，1月30日股价下跌2.11%
证券之星 · 01-30
微芯生物（688321）披露持股5%以上股东部分被冻结股份已解冻的公告，1月30日股价下跌2.11%
微芯生物最新公告：预计2025年净利润5346万元同比扭亏
证券之星 · 01-26
微芯生物最新公告：预计2025年净利润5346万元同比扭亏
每周股票复盘：微芯生物（688321）“微芯转债”预计满足赎回条件
证券之星 · 01-25
每周股票复盘：微芯生物（688321）“微芯转债”预计满足赎回条件
微芯生物（688321）披露“微芯转债”预计满足赎回条件的提示性公告，1月22日股价下跌1.41%
证券之星 · 01-22
微芯生物（688321）披露“微芯转债”预计满足赎回条件的提示性公告，1月22日股价下跌1.41%
每周股票复盘：微芯生物（688321）募资不超9.5亿用于创新药研发
证券之星 · 01-18
每周股票复盘：微芯生物（688321）募资不超9.5亿用于创新药研发
微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%
证券之星 · 01-14
微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%
微芯生物(688321.SH)：西奥罗尼胶囊获药物临床试验批准
智通财经网 · 01-08
微芯生物(688321.SH)：西奥罗尼胶囊获药物临床试验批准
宜明昂科与Axion“分手”；江西省卫健委党组书记被查
21世纪经济报道 · 01-08
宜明昂科与Axion“分手”；江西省卫健委党组书记被查
微芯生物(688321.SH)：澳门药物监督管理局批准西达本胺上市
智通财经 · 01-07
微芯生物(688321.SH)：澳门药物监督管理局批准西达本胺上市
微芯生物最新公告：西格列他钠二甲双胍缓释片临床试验申请获受理
证券之星 · 01-05
微芯生物最新公告：西格列他钠二甲双胍缓释片临床试验申请获受理
每周股票复盘：微芯生物（688321）总经理及法定代表人变更
证券之星 · 01-02
每周股票复盘：微芯生物（688321）总经理及法定代表人变更
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是爱谱沙（西达本胺）、双洛平（西格列他钠）、西奥罗尼、CS23546、CS231295、CS32582、其他在研产品。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":28.03,"timestamp":1774249200000,"preClose":29.3,"halted":0,"volume":9898487,"delay":0,"changeRate":-0.0433,"floatShares":408000000,"shares":443000000,"eps":0.0165,"marketStatus":"已收盘","change":-1.27,"latestTime":"03-23 15:00:00","open":28.92,"high":29.46,"low":27.83,"amount":283000000,"amplitude":0.0556,"askPrice":28.1,"askSize":10,"bidPrice":28.03,"bidSize":67,"shortable":0,"etf":0,"ttmEps":0.0165,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":29.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":32.23,"lowLimit":26.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":442941248,"isCdr":false,"pbRate":8.1,"roa":"--","peRate":1698.787879,"roe":"4.37%","epsLYR":-0.2808,"committee":-0.455378,"marketValue":12416000000,"turnoverRate":0.0243,"status":1,"afterMarket":{"amount":0,"volume":0,"close":28.03,"buyVolume":200,"sellVolume":0,"time":1774251237558,"indexStatus":"已收盘 03-23 15:30:00","preClose":29.3},"floatMarketCap":11431000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2621796910","title":"每周股票复盘：微芯生物（688321）西格列他钠复方制剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796910","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796910?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:55","pubTimestamp":1774115714,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，微芯生物报收于29.3元，较上周的30.4元下跌3.62%。本周，微芯生物3月17日盘中最高价报31.43元。本周关注点公司公告汇总：西格列他钠二甲双胍缓释片获药物临床试验批准通知书。公司公告汇总深圳微芯生物科技股份有限公司及全资子公司成都微芯药业有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意西格列他钠二甲双胍缓释片开展用于2型糖尿病成人患者的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2619155457","title":"微芯生物(688321.SH)：西格列他钠二甲双胍缓释片获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155457","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619155457?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:18","pubTimestamp":1773659918,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 发布公告，公司及全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品西格列他钠二甲双胍缓释片开展临床试验。西格列他钠二甲双胍缓释片是公司自主研发的西格列他钠与二甲双胍的固定剂量复方缓释制剂，通过不同作用机制治疗2型糖尿病，使患者获得更好的血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2619116793","title":"微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619116793","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619116793?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:48","pubTimestamp":1773391703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2618883922","title":"礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2618883922","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618883922?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:00","pubTimestamp":1773248442,"startTime":"0","endTime":"0","summary":"｜2026年3月12日星期四｜NO.1恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603123669204642.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"6afbb4a2a5e710528ea777914b8996d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603123669204642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0882574055.USD","LU2473716301.USD","IE00BFMHRM44.USD","LU1551013425.SGD","LU2272731782.SGD","LU1814569148.SGD","LU0198837287.USD","LU0640476718.USD","LU1366192091.USD","LU2213496289.HKD","SGXZ57979304.SGD","LU2324357040.USD","LU2357305700.SGD","IE00BK4W5L77.USD","LU0210536198.USD","LU0203202063.USD","LU2360106947.USD","LU0106261372.USD","LU2361045086.USD","LU1720051108.HKD","BK1574","LU2028103732.USD","LU2896262040.SGD","LU2322448791.USD","IE0004445015.USD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","LU0672654240.SGD","LU0689472784.USD","IE00BKPKM429.USD","LU1061106388.HKD","LLII","SG9999017495.SGD","LU0320765059.SGD","IE00BFSS7M15.SGD","LU0823434583.USD","LU1267930730.SGD","LU1720051017.SGD","SG9999001176.USD","LU2461242641.AUD","SGXZ51526630.SGD","LU1280957306.USD","LU1064131342.USD","LU2023251221.USD","SG9999015945.SGD","LU2471134879.HKD","IE0004445239.USD","LU2756315318.SGD","LU2237443549.SGD","LU0683600562.USD","LU1868836757.USD","LU2168564149.EUR","LU2023250504.SGD","IE00BFSS8Q28.SGD","LU2168564222.USD","LU2168563687.JPY","LU1232071149.USD","LU2112291526.USD","LU2237443465.HKD","LU1093756325.SGD","SG9999018857.SGD","LU2552382058.USD","LU0158827948.USD","LU2552382132.HKD","LU1623119135.USD","LU2089283258.USD","LU2491050071.SGD","SG9999018865.SGD","LU0109394709.USD","SGXZ81514606.USD","LU2602419157.SGD","LU2471134796.USD","LU2552382215.SGD","LU2089284900.SGD","LU0114720955.EUR","LU0820561818.USD","BK4516","BK4581","IE00BK4W5M84.HKD","IE00B4JS1V06.HKD","LU0708995401.HKD","ELIL","LU1323610961.USD","LU0354030511.USD","LU2746668974.SGD","LLYZ","IE00B7KXQ091.USD","LU1988902786.USD","LU1974910355.USD","SG9999013999.USD","LU1629891620.HKD","SG9999015952.SGD","IE00B1XK9C88.USD","LU2089984988.USD","LU0456855351.SGD","LU0203201768.USD","LU2106854487.HKD","LU0820562030.AUD","LU2023250330.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0225283273.USD","LU0006306889.USD","IE0001KFT4U8.USD","LU0471298694.HKD","LU0353189680.USD","LU0787776722.HKD","LU0385154629.USD","LU0823434740.USD","SG9999014906.USD","LU2471134523.USD","LU2236285917.USD","BK4148","IE00B775H168.HKD","LU0256863902.USD","LU2265009873.SGD","LU2087625088.SGD","LU0417517546.SGD","LU1992135399.USD","09966","BK4588","LU1917777945.USD","LU0786609619.USD","LU1023059063.AUD","BK1161","LU0058720904.USD","LU2456880835.USD","LU2491050154.USD","LU0266013472.USD","IE00BKDWB100.SGD","LU2272731600.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1712237335.SGD","LU0889565916.HKD","LU1069344957.HKD","LU2272731865.HKD","SG9999014880.SGD","LU0256863811.USD","BK4512","LU0096364046.USD","LU0158827781.USD","IE0005OL40V9.USD","IE0009355771.USD","LU0823416689.USD","LU0353189763.USD","BK4534","LU2491049909.HKD","LU2361044949.HKD","LU2108987350.USD","LU1868836591.USD","SG9999015978.USD","LU0109391861.USD","LU1127390331.HKD","LU0348723411.USD","LLYX","LU1868837300.USD","ELIS","LU0354030438.USD","SG9999001176.SGD","LU2237438978.USD","IE00BJJMRY28.SGD","LU1868837136.USD","LU2168564065.EUR","SG9999014914.USD","688321","LU2746668461.USD","LU0466842654.USD","LU0094547139.USD","LU2237443978.SGD","LU0964807845.USD","BK4599","IE00BJJMRZ35.SGD","LU2471134952.CNY","LU2322448957.HKD","LU0079474960.USD","IE00BWXC8680.SGD","IE0002141913.USD","IE00B2B36J28.USD","GB00BDT5M118.USD","LU0943347566.SGD","LU1093756168.USD","BK1515","IE00BJLML261.HKD","LU1551013342.USD","LU0882574139.USD","LU0471298777.SGD","LU0316494557.USD","BK4007","IE00BN29S564.USD","LU0323591593.USD","LU2756315664.SGD","SG9999014898.SGD","LU2417539215.USD","LU2237443622.USD","LU1057294990.SGD","LU1548497426.USD","SGXZ31699556.SGD","LU1992135472.HKD","LU0097036916.USD","LU0320765992.SGD","LU2462157665.USD","LU1804176565.USD","LU1983299246.USD","LU0289739699.SGD","LU2168564495.EUR","LU2063271972.USD","LU2271345857.HKD","SGXZ99366536.SGD","LU0238689110.USD","LU0122379950.USD","LU1868836914.USD","SG9999015986.USD","LU2237443895.HKD","LU2211815571.USD","LU0820561909.HKD","LU0234572021.USD","IE00BJJMRX11.SGD","BK4533","LU0061475181.USD","LU2237443382.USD","LU2264538146.SGD","LU2750360641.GBP","LU2750360997.AUD","LLY","LU2111349929.HKD","BK4585","LU2361044865.SGD","LU0432979614.USD","LU2468319806.SGD","LU1035775433.USD","LU1145028129.USD"],"gpt_icon":1},{"id":"2618923480","title":"微芯生物（688321）披露以集中竞价交易方式首次回购公司股份公告，3月11日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618923480","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618923480?lang=zh_cn&edition=full","pubTime":"2026-03-11 22:13","pubTimestamp":1773238395,"startTime":"0","endTime":"0","summary":"截至2026年3月11日收盘，微芯生物报收于31.17元，较前一交易日下跌1.02%，最新总市值为138.06亿元。该股当日开盘32.13元，最高32.32元，最低31.08元，成交额达3.14亿元，换手率为2.44%。近日，微芯生物披露《关于以集中竞价交易方式首次回购公司股份的公告》。本次回购股份用于员工持股计划或股权激励，回购期限为2026年3月9日至2027年3月8日，回购金额预计8,000万元至12,000万元。本次回购符合相关法规及公司回购方案规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100039208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2618293706","title":"微芯生物(688321.SH)拟8000万元至1.2亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2618293706","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618293706?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:58","pubTimestamp":1773143882,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司拟8000万元至1.2亿元回购股份，回购股份价格不超过48.69元/股，将用于员工持股计划或者股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2616317849","title":"3月3日微芯生物跌6.88%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616317849?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:37","pubTimestamp":1772527020,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日微芯生物跌6.88%，收盘报29.8元，换手率4.13%，成交量16.83万手，成交额5.11亿元。重仓微芯生物的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.5736，较上一交易日下跌2.3%，近一年上涨40.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2614033623","title":"微芯生物（688321）披露向特定对象发行A股股票发行情况报告书，2月25日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614033623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614033623?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:22","pubTimestamp":1772029337,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，微芯生物报收于31.86元，较前一交易日上涨1.56%，最新总市值为129.93亿元。近日，深圳微芯生物科技股份有限公司披露《向特定对象发行A股股票发行情况报告书》。公告显示，本次向特定对象发行A股股票数量为35,133,136股，发行价格为27.04元/股，募集资金总额为949,999,997.44元，扣除发行费用后募集资金净额为932,548,014.28元。本次发行对象共12名，包括湖北省铁路发展基金有限责任公司、财通基金管理有限公司等，新增股份限售期为6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","399300","BK0239","159982"],"gpt_icon":0},{"id":"2608005829","title":"微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608005829","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608005829?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:34","pubTimestamp":1770111245,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant就公司产品西达本胺签署许可及分销协议。Nizhpharm 将自行负责产品在授权地区的研发、上市注册、二次包装、运输及商业化销售工作。Nizhpharm 将按照协议的约定价格从公司采购产品用于授权区域内的商业化销售。Nizhpharm 集团是俄罗斯联邦领先的制药企业之一，拥有逾百年历史。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2607049066","title":"微芯生物（688321）披露持股5%以上股东部分被冻结股份已解冻的公告，1月30日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049066","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607049066?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:19","pubTimestamp":1769782758,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，微芯生物报收于32.01元，较前一交易日下跌2.11%，最新总市值为130.54亿元。该股当日开盘32.7元，最高33.19元，最低31.62元，成交额达3.1亿元，换手率为2.36%。近日，深圳微芯生物科技股份有限公司发布公告称，持股5%以上股东的一致行动人天府清源控股有限公司所持公司8,214,410股股份已于2025年11月26日全部解除司法冻结。本次解冻股份占公司总股本的2.01%。此前，该部分股份因司法原因于2023年8月17日被全部冻结。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2606211100","title":"微芯生物最新公告：预计2025年净利润5346万元同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2606211100","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606211100?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:49","pubTimestamp":1769424590,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，微芯生物发布2025年年度业绩预告，预计归属于上市公司股东的净利润为5346万元左右，将实现扭亏为盈。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600026444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"gpt_icon":0},{"id":"2606123409","title":"每周股票复盘：微芯生物（688321）“微芯转债”预计满足赎回条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2606123409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606123409?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:11","pubTimestamp":1769278270,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，微芯生物报收于34.79元，较上周的35.24元下跌1.28%。本周，微芯生物1月21日盘中最高价报35.93元。微芯生物当前最新总市值141.88亿元，在化学制药板块市值排名40/150，在两市A股市值排名1526/5182。本周关注点公司公告汇总：“微芯转债”已有10个交易日收盘价不低于转股价格的130%，预计可能触发有条件赎回条款。具体决策将在触发条件当日召开董事会后确定，并于次一交易日披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2605242492","title":"微芯生物（688321）披露“微芯转债”预计满足赎回条件的提示性公告，1月22日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605242492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605242492?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:10","pubTimestamp":1769091028,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，微芯生物报收于34.2元，较前一交易日下跌1.41%，最新总市值为139.47亿元。该股当日开盘34.71元，最高34.97元，最低34.06元，成交额达3亿元，换手率为2.14%。近日，深圳微芯生物科技股份有限公司发布《关于“微芯转债”预计满足赎回条件的提示性公告》。公告显示，公司股票自2026年1月9日至1月22日已有10个交易日收盘价不低于“微芯转债”当期转股价格的130%。具体决策将在触发条件当日召开董事会后确定，并于次一交易日披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2604492891","title":"每周股票复盘：微芯生物（688321）募资不超9.5亿用于创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2604492891","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604492891?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:32","pubTimestamp":1768671130,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，微芯生物报收于35.24元，较上周的34.3元上涨2.74%。本周，微芯生物1月15日盘中最高价报36.47元。本周关注点公司公告汇总：拟向特定对象发行A股股票，募集资金总额不超过9.5亿元，用于创新药研发等项目。关于2026年度日常关联交易额度预计的公告深圳微芯生物科技股份有限公司预计2026年度与关联方成都微芯新域生物技术有限公司、成都安信国生微芯医药健康股权投资基金合伙企业发生日常关联交易，合计金额不超过1,300万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","06978","BK1161","688321","BK0239"],"gpt_icon":0},{"id":"2603614430","title":"微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603614430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603614430?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:18","pubTimestamp":1768400297,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，微芯生物报收于34.7元，较前一交易日上涨1.85%，最新总市值为141.51亿元。该股当日开盘33.83元，最高36.22元，最低33.73元，成交额达8.2亿元，换手率为5.75%。公司近日发布公告称，深圳微芯生物科技股份有限公司拟向特定对象发行A股股票，募集资金总额不超过9.5亿元，用于创新药研发项目、彭州微芯原创新药制造基地（一阶段）项目及补充流动资金。本次发行股票数量不超过58,125,305股，不超过发行前总股本的30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","688321","BK0239","06978","159992"],"gpt_icon":0},{"id":"2601035936","title":"微芯生物(688321.SH)：西奥罗尼胶囊获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601035936","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601035936?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:58","pubTimestamp":1767859111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)公告，公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品西奥罗尼胶囊开展联合特瑞普利单抗及化疗一线治疗转移性胰腺导管腺癌的临床研究。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微芯生物(688321.SH)：西奥罗尼胶囊获药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2601533894","title":"宜明昂科与Axion“分手”；江西省卫健委党组书记被查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601533894","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601533894?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:41","pubTimestamp":1767832919,"startTime":"0","endTime":"0","summary":"政策动向国家药监局：优化临床急需境外已上市药品审评审批央视新闻消息显示，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导向，鼓励申请人在中国开展全球同步研发、同步申报上市；鼓励临床急需境外已上市的原研药及仿制药在境内申报，对于符合要求的可纳入优先审评审批范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601083612141760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612141760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU1997244956.HKD","600276","BK0028","BK0188","LU1064131003.USD","LU2097828557.USD","LU1328615791.USD","LU2580892862.HKD","688321","BK0060","BK0251","688759","LU1781817850.SGD","LU2097828474.EUR","LU2328871848.SGD","LU2495084118.USD","BK0012","LU1820825898.SGD","BK0114","LU1655091616.SGD","BK0236","BK0183","BK0239","LU2097828805.USD","BK0196","LU1997245177.USD","LU2580892789.USD","LU1580142542.USD","BK0096","BK0077","LU2148510915.USD","LU2488822045.USD","LU1255011170.USD","LU2097828714.EUR","LU0405327148.USD","LU2289578879.USD","002173","300653","LU1146622755.USD","LU1969619763.USD","LU1997245094.SGD","LU0405327494.USD","LU1064130708.USD","BK0046"],"gpt_icon":0},{"id":"2601252873","title":"微芯生物(688321.SH)：澳门药物监督管理局批准西达本胺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601252873","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601252873?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:45","pubTimestamp":1767775530,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 发布公告，近日，中华人民共和国澳门特别行政区药物监督管理局官方网站公示，ISAF 批准公司的西达本胺片上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微芯生物(688321.SH)：澳门药物监督管理局批准西达本胺上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2601000851","title":"微芯生物最新公告：西格列他钠二甲双胍缓释片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000851","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000851?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:10","pubTimestamp":1767607805,"startTime":"0","endTime":"0","summary":"微芯生物公告称，公司及全资子公司成都微芯药业近日收到国家药监局签发的境内生产药品注册临床试验的《受理通知书》，公司自主研发的西格列他钠二甲双胍缓释片治疗2型糖尿病成人患者的临床试验申请获得受理。该药是公司自主研发的西格列他钠与二甲双胍的固定剂量复方缓释制剂，通过不同作用机制治疗2型糖尿病，使患者获得更好的血糖控制。目前，全球尚无PPAR全激动剂与二甲双胍的复方制剂进入临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2600352360","title":"每周股票复盘：微芯生物（688321）总经理及法定代表人变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2600352360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600352360?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:10","pubTimestamp":1767291021,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，微芯生物报收于29.01元，较上周的28.18元上涨2.95%。本周关注点公司公告汇总：中证鹏元关注微芯生物总经理及法定代表人变更事项，维持主体信用等级A+。公司公告汇总中证鹏元关于关注深圳微芯生物科技股份有限公司总经理、法定代表人变更事项的公告中证鹏元关注微芯生物总经理及法定代表人变更事项，原总经理XIANPING LU博士变更为黎建勋先生，法定代表人由XIANPING LU博士变更为海鸥女士，XIANPING LU博士仍任董事长及实际控制人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774294167993,"stockEarnings":[{"period":"1week","weight":-0.0935},{"period":"1month","weight":-0.1194},{"period":"3month","weight":-0.0186},{"period":"6month","weight":-0.1547},{"period":"1year","weight":0.5367},{"period":"ytd","weight":-0.0407}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24446人(较上一季度增加25.25%)","perCapita":"16681股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"44294万元","survey":" 深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是爱谱沙（西达本胺）、双洛平（西格列他钠）、西奥罗尼、CS23546、CS231295、CS32582、其他在研产品。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}